Abstract
A series of 48 commercial benzaldehydes have been evaluated for their in vitro antibacterial activity against Mycobacterium tuberculosis H37Rv, using the Alamar Blue susceptibility test and the activity expressed as the minimum inhibitory concentration (MIC) in μg/mL. Benzaldehydes 39 and 41 exhibited a significant activity at 3.12 μg/mL. Although commercial benzaldehydes have been largely used by many research groups in search of news TB-drugs, they had not been tested previously against Mycobacterium tuberculosis. This study adds important information to the rational design of new lead anti-TB drugs.
Keywords: Antimycobacterial evaluation, Alamar Blue assay, Benzaldehydes, Cytotoxicity, Drugs, Tuberculosis, Mycobacterium tuberculosis, multidrug-resistant tuberculosis, MDR-TB, drug-resistant tuberculosis, XDR-TB, Rifampin, Isoniazid, Cell Viability Assay, RPMI 1640, DMSO, MABA, BACTEC, SAR, Mosmans's MTT
Letters in Drug Design & Discovery
Title: Evaluation of Substituted Benzaldehydes Against Mycobacterium tuberculosis
Volume: 7 Issue: 10
Author(s): Marcelle de Lima Ferreira, Andre Luis Peixoto Candea, Maria das Gracas Muller de Oliveira Henriques, Maria Cristina Silva Lourenco, Carlos Roland Kaiser and Marcus Vinicius Nora de Souza
Affiliation:
Keywords: Antimycobacterial evaluation, Alamar Blue assay, Benzaldehydes, Cytotoxicity, Drugs, Tuberculosis, Mycobacterium tuberculosis, multidrug-resistant tuberculosis, MDR-TB, drug-resistant tuberculosis, XDR-TB, Rifampin, Isoniazid, Cell Viability Assay, RPMI 1640, DMSO, MABA, BACTEC, SAR, Mosmans's MTT
Abstract: A series of 48 commercial benzaldehydes have been evaluated for their in vitro antibacterial activity against Mycobacterium tuberculosis H37Rv, using the Alamar Blue susceptibility test and the activity expressed as the minimum inhibitory concentration (MIC) in μg/mL. Benzaldehydes 39 and 41 exhibited a significant activity at 3.12 μg/mL. Although commercial benzaldehydes have been largely used by many research groups in search of news TB-drugs, they had not been tested previously against Mycobacterium tuberculosis. This study adds important information to the rational design of new lead anti-TB drugs.
Export Options
About this article
Cite this article as:
de Lima Ferreira Marcelle, Luis Peixoto Candea Andre, das Gracas Muller de Oliveira Henriques Maria, Cristina Silva Lourenco Maria, Roland Kaiser Carlos and Vinicius Nora de Souza Marcus, Evaluation of Substituted Benzaldehydes Against Mycobacterium tuberculosis, Letters in Drug Design & Discovery 2010; 7 (10) . https://dx.doi.org/10.2174/1570180811007010754
DOI https://dx.doi.org/10.2174/1570180811007010754 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Clostridium difficile Infection in Children with Inflammatory Bowel Disease: Current Evidence
Current Pharmaceutical Design Coffee and Depression: A Short Review of Literature
Current Pharmaceutical Design Meet Our Editorial Board Member
Infectious Disorders - Drug Targets Detection of the Incidence of Infections and Acute Biochemical Changes in Diffused Large B-Cell Lymphoma Patients Treated with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (CHOP) with and without Rituximab
Current Drug Safety Assessment of Glycoproteins Dynamics from Computer Simulations
Mini-Reviews in Organic Chemistry Identification of Novel Anti-inflammatory Agents from Ayurvedic Medicine for Prevention of Chronic Diseases: “Reverse Pharmacology” and “Bedside to Bench” Approach
Current Drug Targets Tubercidin and Related Analogues: An Inspiration for 50 years in Drug Discovery
Current Organic Chemistry Solid Lipid Nanoparticles: A Potential Approach for Drug Delivery System
Nanoscience & Nanotechnology-Asia Patent Selections
Recent Patents on DNA & Gene Sequences Microwave-assisted Synthesis of 2-Styrylquinoline-4-carboxylic Acids as Antitubercular Agents
Medicinal Chemistry New Perspectives of Infections in Cardiovascular Disease
Current Cardiology Reviews Lewis Acid Promoted, One-Pot Synthesis of Fluoroquinolone Clubbed 1,3,4-Thiadiazole Motifs under Microwave Irradiation: Their Biological Activities
Current Microwave Chemistry A Novel Method to Synthesize 4-Aryl-1H-1,2,3-Triazoles and its Antihepatoma Activity
Anti-Cancer Agents in Medicinal Chemistry Nanochemistry-Based Immunotherapy for HIV-1
Current Medicinal Chemistry Synthesis and Anti-Proliferative Evaluations of New Heterocyclic Derivatives Using 5,6,8,9-Tetrahydropyrazolo[5,1-b]quinazolin-7(3H)-one Derivatives Derived from Cyclohexa-1,4-dione
Anti-Cancer Agents in Medicinal Chemistry New Approaches to Tuberculosis - Novel Drugs Based on Drug Targets Related to Toll-Like Receptors in Macrophages
Current Pharmaceutical Design Anti-cytokines and Cytokines in the Treatment of Rheumatoid Arthritis
Current Pharmaceutical Design Flavones as a Privileged Scaffold in Drug Discovery: Current Developments
Current Organic Synthesis Antimalarial Drug Development: Past to Present Scenario
Mini-Reviews in Medicinal Chemistry Medicinal Plants and Cancer Chemoprevention
Current Drug Metabolism